{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n Recent studies have underscored the importance of molecular precision in clinical diagnostics and prognostication. For example, research on breast cancer HER2 testing revealed that the use of alternative control probes in fluorescence in situ hybridization (FISH) can falsely elevate HER2 ratios due to heterozygous deletions in control genomic sites, leading to potential misclassification of tumors."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Similarly, chromosomal microarray analysis has demonstrated that absence of mosaicism in peripheral blood does not always reflect its status in other tissues, emphasizing the need for comprehensive molecular assessments."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In the context of glioma, an integrated risk assessment model incorporating a panel of five long non‑coding RNAs—including CDRT7—has emerged as a promising prognostic tool."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": " Within this model, CDRT7 is co‑expressed with multiple genes involved in critical cellular processes such as cytoskeletal organization, cell adhesion, and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. These functional associations suggest that CDRT7 not only serves as an independent prognostic marker but may also play a role in modulating glioma progression and cellular dynamics. Thus, the inclusion of CDRT7 in risk stratification models highlights its potential utility as both a biomarker for accurate outcome prediction and a candidate for further functional investigation in glioma biology.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Michael F Press, Jose A Seoane, Christina Curtis, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "JAMA Oncol (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1001/jamaoncol.2018.6012"}], "href": "https://doi.org/10.1001/jamaoncol.2018.6012"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30520947"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30520947"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Chandni V Pal, Tanya N Eble, Rachel D Burnside, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Variable levels of tissue mosaicism can confound the interpretation of chromosomal microarray results from peripheral blood."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur J Med Genet (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ejmg.2014.03.001"}], "href": "https://doi.org/10.1016/j.ejmg.2014.03.001"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24636861"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24636861"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Chenggong Hu, Yongfang Zhou, Chang Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Risk assessment model constructed by differentially expressed lncRNAs for the prognosis of glioma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncol Rep (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/or.2018.6639"}], "href": "https://doi.org/10.3892/or.2018.6639"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30106138"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30106138"}]}]}]}